Actively Recruiting
Randomized Controlled Trial Evaluating Weekly Tirzepatide Injections for Adults With Moderate or Severe Methamphetamine Use Disorder
Led by University of Texas Southwestern Medical Center · Updated on 2026-10-26
228
Participants Needed
4
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating tirzepatide, a dual GLP-1glucose-dependent insulinotropic peptide receptor agonist, for treating adults with moderate or severe methamphetamine use disorder MtUD. This phase 2, randomized, double-blind, placebo-controlled trial aims to assess the tolerability, safety, and preliminary effectiveness of tirzepatide in reducing methamphetamine use. The study is sponsored by University of Texas Southwestern Medical Center and addresses an important need as no FDA-approved treatments currently exist for MtUD. Participants will be randomly assigned to receive once-weekly subcutaneous injections of either tirzepatide or saline placebo for 26 weeks. Tirzepatide dosing starts at 2.5 mg per week and is increased every four weeks by 2.5 mg to a maximum of 15 mg or the highest tolerated dose. After the 26-week treatment period, participants will be followed for an additional 6 weeks to monitor safety and outcomes. Throughout the 32-week study period, participants will complete self-assessments, undergo brief physical exams and medical and psychiatric history reviews, and provide urine and blood samples. Medical management sessions and weekly medication injections are part of the study procedures. Researchers will measure treatment response, methamphetamine use reduction, craving levels, remission status, and safety events to evaluate tirzepatides effects in this population.
CONDITIONS
Brief Title
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
Research Team
E
Elizabeth Dedrick, BS
S
Shavonna Williams
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here